BOLERO -- another remarkable step in treatment of breast cancer
The expansion of molecular genetic knowledge leads to targeted therapy which is a common part of cancer treatment. Targeted agents also exist for breast cancer. However, new efficient molecules are urgently needed. On one hand, there are cancer subgroups where we do not have efficient targeted drugs, on the other hand, the results of established cancer therapies can be improved by interfering with another signal transduction pathway. Everolimus is a targeted agent which was effective in several clinical trials and became registered for treatment of hormone receptor positive breast cancer. This article summarizes the results of published breast cancer everolimus trials. The results of two phase 3 trials are available. In the BOLERO-2 trial exemestane was compared with the combination of exemestane and everolimus, while in BOLERO-3 trial trastuzumab and vinorelbine were investigated with or without everolimus. In both trials the progression-free survival was significantly longer in the experimental arm. The overall survival data of BOLERO-2 trial, a secondary end point, are also available. The 4.4 month benefit in the experimental arm is clinically important but it has not reached the level of statistical significance. We have not had biomarkers so far that could help us to identify a subgroup of cancers sensitive to everolimus.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Magyar onkologia - 58(2014), 2 vom: 01. Juni, Seite 128-32 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
BOLERO -- újabb jelentős lépés az emlődaganatok kezelésében |
|---|
| Beteiligte Personen: |
Rubovszky, Gábor [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 16.10.2014 Date Revised 03.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM239956273 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM239956273 | ||
| 003 | DE-627 | ||
| 005 | 20231224121058.0 | ||
| 007 | tu | ||
| 008 | 231224s2014 xx ||||| 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n0799.xml |
| 035 | |a (DE-627)NLM239956273 | ||
| 035 | |a (NLM)25010761 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Rubovszky, Gábor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BOLERO -- another remarkable step in treatment of breast cancer |
| 246 | 3 | 3 | |a BOLERO -- újabb jelentős lépés az emlődaganatok kezelésében |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.10.2014 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The expansion of molecular genetic knowledge leads to targeted therapy which is a common part of cancer treatment. Targeted agents also exist for breast cancer. However, new efficient molecules are urgently needed. On one hand, there are cancer subgroups where we do not have efficient targeted drugs, on the other hand, the results of established cancer therapies can be improved by interfering with another signal transduction pathway. Everolimus is a targeted agent which was effective in several clinical trials and became registered for treatment of hormone receptor positive breast cancer. This article summarizes the results of published breast cancer everolimus trials. The results of two phase 3 trials are available. In the BOLERO-2 trial exemestane was compared with the combination of exemestane and everolimus, while in BOLERO-3 trial trastuzumab and vinorelbine were investigated with or without everolimus. In both trials the progression-free survival was significantly longer in the experimental arm. The overall survival data of BOLERO-2 trial, a secondary end point, are also available. The 4.4 month benefit in the experimental arm is clinically important but it has not reached the level of statistical significance. We have not had biomarkers so far that could help us to identify a subgroup of cancers sensitive to everolimus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Androstadienes |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Aromatase Inhibitors |2 NLM | |
| 650 | 7 | |a Receptors, Estrogen |2 NLM | |
| 650 | 7 | |a Receptors, Progesterone |2 NLM | |
| 650 | 7 | |a Vinblastine |2 NLM | |
| 650 | 7 | |a 5V9KLZ54CY |2 NLM | |
| 650 | 7 | |a Everolimus |2 NLM | |
| 650 | 7 | |a 9HW64Q8G6G |2 NLM | |
| 650 | 7 | |a MTOR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a exemestane |2 NLM | |
| 650 | 7 | |a NY22HMQ4BX |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Vinorelbine |2 NLM | |
| 650 | 7 | |a Q6C979R91Y |2 NLM | |
| 650 | 7 | |a Sirolimus |2 NLM | |
| 650 | 7 | |a W36ZG6FT64 |2 NLM | |
| 700 | 1 | |a Láng, István |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Magyar onkologia |d 1961 |g 58(2014), 2 vom: 01. Juni, Seite 128-32 |w (DE-627)NLM092654185 |x 2060-0399 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2014 |g number:2 |g day:01 |g month:06 |g pages:128-32 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2014 |e 2 |b 01 |c 06 |h 128-32 | ||